FDA News

FDA restructures, renames office that reviews cancer therapies

November 6, 2019
The FDA office that reviews applications for cancer therapies has been renamed and reorganized. The Center for Drug Evaluation and Research’s…

Commentary

Lymphatic vessels active, anatomical determinants of effective antitumor immunity

November 1, 2019
By Amanda W. Lund, PhD The prevailing model of lymphatic vessel involvement in cancer is that tumor cells use lymphatic vessels as passive escape…

Trend Watch

MD Anderson, Ziopharm renew R&D agreement to include T-cell receptor-based therapies

October 31, 2019
The University of Texas MD Anderson Cancer Center has announced a new research and development agreement with partner Ziopharm Oncology for the…

Hematologists, oncologists elected to National Academy of Medicine

October 30, 2019
The National Academy of Medicine announced the election of 90 regular members and 10 international members. Election to the academy —…

FDA News

FDA grants CAR T-cell therapy RMAT designation for multiple myeloma

October 28, 2019
The FDA has granted its regenerative medicine advanced therapy designation to CT053, a chimeric antigen receptor T-cell therapy for the treatment of…

Trend Watch

FDA Grants CAR T-cell Therapy RMAT Designation for Multiple Myeloma

Cell Therapy Next, November/December 2019
The FDA has granted its regenerative medicine advanced therapy designation to CT053, a chimeric antigen receptor T-cell therapy for the treatment of…

New president of AABB begins term

October 23, 2019
Beth H. Shaz, MD, has started her 2019-2020 term as president of AABB. Shaz is executive vice president and chief medical and scientific…

Clinical Trials Snapshot

T-cell Responses to Concurrent HIV and Herpesvirus Infections

Cell Therapy Next, October/November 2019
An observational, prospective cohort study to discover new information about how HIV and herpes viruses interact with the immune system, with a goal…

Clinical Trials Snapshot

TCR-engineered T Cells in Solid Tumors (ACTengine)

Cell Therapy Next, October/November 2019
Phase 1 study evaluating the safety and tolerability of genetically modified autologous T cells expressing a T-cell receptor recognizing a…

Trend Watch

RFTCA Purchases Cell-Based Technology to Develop Cure for HIV/AIDS

Cell Therapy Next, October/November 2019
The Research Foundation to Cure AIDS has purchased licensing rights to Chromovert, a cell-based biotechnology that detects and purifies rare cells…

Clinical Trials Snapshot

NY-ESO-1 TCR Engineered T Cell and HSC After Melphalan Conditioning Regimen in Treating Participants with Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Cell Therapy Next, October/November 2019
Phase 1, open-label study evaluating the safety and efficacy of adoptive transfer of autologous NY-ESO-1 CD8-TCR engineered T cells and NY-ESO-1…

Feature

Hope vs Hype: Managing Patient Expectations for CAR T-Cell Therapy

Cell Therapy Next, October/November 2019
Imagine a young adult male in his late 20s picks up his cell phone and calls his mother. Overtly emotional and on the verge of releasing a full-out…

Clinical Trials Snapshot

HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

Cell Therapy Next, October/November 2019
Phase 1 study to determine the safety and feasibility of using HERV-E TCR-transduced autologous T Cells in patients with metastatic clear-cell…

Clinical Trials Snapshot

HA-1 T TCR T Cell Immunotherapy for the Treating of Patients with Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Cell Therapy Next, October/November 2019
Phase 1 study of adoptive immunotherapy with CD8+ and CD4+ memory T cells transduced to express an HA-1-specific T cell receptor for children and…

Cover Story

Developing a Pause Button for CAR T-Cell Therapy

Cell Therapy Next, October/November 2019
Chimeric antigen receptor T-cell therapy has proven to be a life-changing development for those with advanced, treatment refractory leukemia and…

Trend Watch

Cameron Turtle Receives Fred Hutch’s Endowed Chair for Immunotherapy

Cell Therapy Next, October/November 2019
Cameron Turtle, MD, PhD, a pioneer in the field of chimeric antigen receptor T-cell therapy, has been honored as the inaugural recipient of the…

Clinical Trials Snapshot

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Cell Therapy Next, October/November 2019
Phase 1 dose-escalation clinical trial to determine the phase 2 dose of autologous TIL 1383I TCR gene-modified T cells using a retrovirus for…

Feature

Seattle Cancer Care Alliance opens its doors to share its cellular therapy experience

September 18, 2019
The Seattle Cancer Care Alliance, the clinical care partner of the Fred Hutchinson Cancer Research Center, has been at the forefront of cellular…

Meeting NewsPerspective

Induction radiation therapy before CAR-T reduces treatment-related toxicities

September 17, 2019
Patients who received radiation therapy before chimeric antigen receptor T-cell therapy for relapsed or refractory non-Hodgkin lymphoma were less…

Trend Watch

Penn, Novartis end groundbreaking CAR-T relationship with new, more focused collaboration

September 16, 2019
The 7-year research and development alliance between Novartis and the University of Pennsylvania has concluded, with both organizations entering into…